Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
1.285
-0.055 (-4.10%)
Oct 10, 2025, 1:23 PM EDT - Market open
Ernexa Therapeutics Revenue
Ernexa Therapeutics had revenue of $488.00K in the twelve months ending June 30, 2025, up 201.23% year-over-year. In the year 2024, Ernexa Therapeutics had annual revenue of $582.00K with 755.88% growth.
Revenue (ttm)
$488.00K
Revenue Growth
+201.23%
P/S Ratio
7.97
Revenue / Employee
$81,333
Employees
6
Market Cap
9.86M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 582.00K | 514.00K | 755.88% |
Dec 31, 2023 | 68.00K | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | 39.61M | -7.06M | -15.12% |
Dec 31, 2018 | 46.67M | 4.12M | 9.69% |
Dec 31, 2017 | 42.55M | -2.08M | -4.65% |
Dec 31, 2016 | 44.62M | -4.41M | -9.00% |
Dec 31, 2015 | 49.04M | -3.05M | -5.86% |
Dec 31, 2014 | 52.09M | 4.59M | 9.67% |
Dec 31, 2013 | 47.50M | 23.43M | 97.38% |
Dec 31, 2012 | 24.06M | 194.00K | 0.81% |
Dec 31, 2011 | 23.87M | -1.44M | -5.69% |
Dec 31, 2010 | 25.31M | -505.00K | -1.96% |
Dec 31, 2009 | 25.81M | -1.68M | -6.12% |
Dec 31, 2008 | 27.50M | -3.05M | -9.97% |
Dec 31, 2007 | 30.54M | -2.44M | -7.41% |
Dec 31, 2006 | 32.99M | 2.24M | 7.27% |
Dec 31, 2005 | 30.75M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ERNA News
- 9 days ago - Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa - GlobeNewsWire
- 11 days ago - Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit - GlobeNewsWire
- 23 days ago - Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research - GlobeNewsWire
- 4 weeks ago - Ernexa Therapeutics Provides Update on Operational Excellence and Performance - GlobeNewsWire
- 5 weeks ago - Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 3 months ago - Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development - GlobeNewsWire
- 3 months ago - Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement - GlobeNewsWire